BCaP-37 Xenograft Model Service for Breast Cancer

The BCaP-37 xenograft model is a highly reliable in vivo platform for evaluating the therapeutic potential of novel compounds against human breast adenocarcinoma, offering consistent growth kinetics and clinical relevance. Alfa Cytology specializes in providing comprehensive BCaP-37 xenograft model services, combining surgical precision with advanced analytical readouts to empower your oncology drug discovery programs.

Overview of BCaP-37 Xenograft Model for Breast Cancer

The BCaP-37 cell line is a well-established human breast cancer model originally derived from an invasive ductal carcinoma. As an in vivo xenograft model, BCaP-37 is widely recognized for its robust tumorigenicity and its ability to maintain the histological and molecular characteristics of the original human malignancy. This model is particularly valued for its predictable growth patterns and sensitive response to a variety of cytotoxic agents and targeted therapies.

Utilizing the BCaP-37 model allows researchers to investigate tumor proliferation, survival signaling, and the efficacy of anti-cancer candidates in a complex biological environment. At Alfa Cytology, we ensure that the BCaP-37 model is established using standardized protocols to minimize variability.

Fig 1. Sauchinone significantly inhibited breast cancer migration and invasion. (Hu X, et al., 2023)

Cell Line Information: BCaP-37

The BCaP-37 cell line exhibits typical epithelial morphology and is characterized by its stable growth profile under controlled laboratory conditions.

At Alfa Cytology, we understand that the quality of your preclinical data depends on the integrity of the tumor model. Our scientific team has optimized the BCaP-37 inoculation process, utilizing specialized techniques to ensure optimal tumor-host interaction and localized growth. By partnering with Alfa Cytology, you gain access to a dedicated CRO that prioritizes scientific rigor and transparent reporting, ensuring that your BCaP-37 in vivo studies yield the actionable insights required to advance your pipeline.

Our Services

Workflow of BCaP-37 Xenograft Model Construction

The construction of a BCaP-37 xenograft model at Alfa Cytology follows a structured and validated workflow:

• Cell Expansion: BCaP-37 cells are cultured in vitro using certified media to ensure they are in the exponential growth phase and free from contamination.
• Host Preparation: Female immunocompromised mice are selected and acclimatized in our standardized facilities to ensure a stable baseline for the study.
• Inoculation: A precise concentration of BCaP-37 cells is prepared in a serum-free medium (often with a matrix carrier) and injected in vivo either subcutaneously or orthotopically.
• Growth Tracking: Following engraftment, tumor volumes and animal body weights are monitored using digital calipers and sensitive weighing scales to establish a detailed growth curve.
• Randomization & Grouping: Once the BCaP-37 tumors reach a statistically significant volume, animals are randomized into experimental groups to ensure unbiased therapeutic evaluation.

Fig 2. BCaP-37 Xenograft Model Construction Workflow

Case Study - BCaP-37 Xenograft Model Development

In a recent drug efficacy evaluation, Alfa Cytology established the BCaP-37 xenograft model to test a novel small-molecule inhibitor. The model demonstrated a 100% tumor take rate with highly uniform growth across the control cohorts. Upon administration of the test compound, a significant dose-dependent tumor growth inhibition (TGI) was observed in vivo. The study provided our client with robust evidence of therapeutic activity, supported by detailed histological analysis of the BCaP-37 tumor tissues at the study endpoint.

Why Choose Alfa Cytology?

• Optimized Protocols: Proven success in establishing BCaP-37 models with exceptional reproducibility and minimal variability.
• Technical Excellence: Proficiency in various inoculation routes and specialized surgical procedures.
• Integrated Services: Comprehensive support from initial study design to advanced downstream analysis (e.g., IHC, PK/PD).
• Data Transparency: Rigorous quality control and detailed reporting designed to meet industry standards for regulatory filings.

Contact Us

Are you looking for a reliable partner to conduct your BCaP-37 xenograft studies? Our team of oncology experts is ready to provide the technical precision and scientific insight your project demands. Please reach out to us today to discuss your experimental goals, or contact us directly to request a customized quote for your BCaP-37 research program with Alfa Cytology.

For research use only. Not intended for any clinical use.